6550 Polaris Pharma-KY Announces Capital Increase of $10 Million to 100% Subsidiary TDW HK Limited

Release Date: July 2, 2026 Statement Date: July 1, 2026 Statement Time: 17:01:17 Company Code: 6550 Company Name: Polaris Pharma-KY Purpose: Announcement of proposed capital increase to 100% subsidiary TDW HK Limited Applicable Clause: Clause 20 Factual Date: July 1, 2026

Details: 1. Name and nature of the subject matter (for preferred shares, specify dividend rate and other conditions): Ordinary shares of TDW HK Limited

2. Factual date: July 1, 2026

3. Board approval date: July 1, 2026

4. Other approval dates: Not applicable

5. Transaction quantity, unit price, and total transaction amount: Number of units: 10,000,000 shares Unit price: USD 1 per share Total transaction amount: USD 10,000,000

6. Counterparty and its relationship with the company (if individual and not a related party, name may be omitted): Wholly-owned subsidiary of the company

7. If the counterparty is a related party, state the reason for selection, previous transferor, relationship among previous transferor, company, and counterparty, transfer date, and amount: Not applicable

8. If the owner of the subject matter was a related party of the company within the past five years, disclose the acquisition and disposal date, price, and relationship with the company at the time: Not applicable

9. Matters related to the disposal of receivables (including types of collateral, names of related parties if receivables are from related parties, and book value of receivables disposed): Not applicable

10. Gain (or loss) from disposal (not applicable for acquisition of securities) (if deferred, explain recognition status): Not applicable

11. Delivery or payment terms (including payment period and amount), contractual restrictions, and other important agreements: Number of units: 10,000,000 shares Unit price: USD 1 per share Total transaction amount: USD 10,000,000

12. Decision-making method for the transaction, reference basis for pricing, and decision-making body: Approved by the board of directors

13. Net asset value per share of the securities-issuing company: NT$30.43

14. Cumulative holdings of the securities involved in this transaction (including this transaction) to date, including quantity, amount, ownership percentage, and any restrictions on rights (e.g., pledge status): Quantity: 128,750,001 shares Amount: USD 128,750,000 Ownership percentage: 100% Restrictions: None

15. Proportion of securities investments (including this transaction) under Article 3 of the 'Asset Acquisition and Disposal Rules for Publicly Issued Companies' to the company's total assets and equity attributable to owners of the parent in the latest financial statements, and the amount of working capital in the latest financial statements: Percentage of total assets: 50.88% Percentage of equity attributable to owners of the parent: 80.86% Working capital: NT$1,898,318 thousand

16. Broker and brokerage fees: Not applicable

17. Specific purpose or use of the acquisition or disposal: Long-term investment

18. Dissenting opinions from directors regarding this transaction: None

19. Whether this transaction is a related-party transaction: Yes

20. Date of approval by auditor or audit committee: July 1, 2026

21. Whether the accountant issued a non-rational opinion: Not applicable

22. Name of accounting firm: Not applicable

23. Name of accountant: Not applicable

24. Accountant's license number: Not applicable

25. Whether it involves a change in business model: No

26. Explanation of business model change: Not applicable

27. Transaction history with the counterparty in the past year and expected in the next year: Not applicable

28. Source of funds: Not applicable

29. Previous date of material information disclosure on the same event: Not applicable

30. Other explanatory matters: None